Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 16, Issue 5, Pages 301-304Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd.2017.84
Keywords
-
Ask authors/readers for more resources
The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
